Returns | 1W : 3.9% , 1M : 15.8%,1Y : 64.7% |
LT :   |
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive] Debt : High |
ST :   |
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward Pledged Shares : None or < 25% |
Peers & Returns | 1W | 1M | 1Y |
HIKAL | 3.9% | 15.8% | 64.7% |
SUN PHARMACEUTICAL INDUSTRIES | 1.4% | 6.7% | 41% |
DR REDDYS LABORATORIES | 2.8% | 12.7% | 27.3% |
DIVIS LABORATORIES | 1.9% | 12.1% | 58.1% |
CIPLA | 6.4% | 16.6% | 54.3% |
BIOCON | -1.8% | 4.3% | 20.1% |
AUROBINDO PHARMA | 1% | 14.2% | 77.7% |
LUPIN | -2.2% | -0.5% | 29.5% |
TORRENT PHARMACEUTICALS | 1.8% | 7.7% | 11.6% |
Ratio | Value |
---|---|
P/E P/B P/S |
26.22
P/E Calculated based on EPS of 6.85
[ Mar2020 - Standalone Results ] 2.71
P/B Calculated based on Book Value of 66.22
[ Mar2020 - Standalone Results ] 1.52
P/S Calculated based on Revenues of 1456.87 Cr
[ TTM - Standalone Results ] |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
25% -1% 25% |
Pledged Shares |
0 % |
---|---|
As on : Sep2020 | |
If less than 25% | Good |
If between 25% and 50% | Neutral |
If greater than 50% | Bad |
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE HEALTHCARE | 1.2% | 9.2% | 53% |
S&P BSE ALLCAP | -1.9% | -1.7% | 68.2% |
S&P BSE SMALL CAP | -2.7% | -0.4% | 100.6% |
S&P BSE MIDSMALLCAP | -2.8% | -0.8% | 87.9% |